Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

Area of Science:

• Oncology
• Cardiology
• Molecular Biology

Background:

• Recent advancements in cancer therapy include targeted drugs, especially tyrosine kinase inhibitors.
• These targeted therapies are crucial for treating cancers driven by specific genetic mutations or amplifications.
• A significant concern is the potential cardiotoxicity associated with these effective cancer treatments.

Purpose of the Study:

• To review the cardiotoxicity of cancer drugs targeting tyrosine kinases.
• To elucidate the fundamental mechanisms linking tyrosine kinase inhibition to cardiomyocyte dysfunction and death.
• To compare the effects of these drugs on cancer cells versus heart cells.

Main Methods:

• Literature review of studies on tyrosine kinase inhibitors and cardiotoxicity.
• Analysis of molecular signaling pathways involved in tumorigenesis and cardiac function.
• Comparative examination of drug effects in cancer and cardiac contexts.

Main Results:

• Tyrosine kinase inhibitors can disrupt critical signaling pathways in cardiomyocytes.
• This disruption leads to cardiomyocyte dysfunction and/or apoptosis, causing heart damage.
• The mechanisms of cardiotoxicity differ from the therapeutic actions in cancer cells.

Conclusions:

• Understanding the mechanisms of cardiotoxicity is essential for managing side effects of targeted cancer therapies.
• Further research is needed to develop strategies for mitigating cardiac risks while maintaining therapeutic efficacy.
• Balancing cancer treatment benefits with cardiac safety is a key challenge in oncology.